Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May;241(10):1033-41.
doi: 10.1177/1535370216647130. Epub 2016 May 10.

The use of CD47-modified biomaterials to mitigate the immune response

Jillian E Tengood  1 , Robert J Levy  1 , Stanley J Stachelek  2
Affiliations
Review

The use of CD47-modified biomaterials to mitigate the immune response

Jillian E Tengood et al. Exp Biol Med (Maywood). 2016 May.

Abstract

Addressing the aberrant interactions between immune cells and biomaterials represents an unmet need in biomaterial research. Although progress has been made in the development of bioinert coatings, identifying and targeting relevant cellular and molecular pathways can provide additional therapeutic strategies to address this major healthcare concern. To that end, we describe the immune inhibitory motif, receptor-ligand pairing of signal regulatory protein alpha and its cognate ligand CD47 as a potential signaling pathway to enhance biocompatibility. The goals of this article are to detail the known roles of CD47-signal regulatory protein alpha signal transduction pathway and to describe how immobilized CD47 can be used to mitigate the immune response to biomaterials. Current applications of CD47-modified biomaterials will also be discussed herein.

Keywords: CD47; biomaterials; inflammation; signal regulatory protein alpha.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Model ITIM receptor. The ITIM family receptors have a transmembrane region and a extracellular ligand binding domain. A cytoplasmic ITIM domain interacts with secondary cell signaling molecules such as SHP-1 and SHP-2. Through a series of transphosphorylation events, ITIM receptors inhibit immune cell activation events such as cytokine release and phagocytosis (A color version of this figure is available in the online journal.)
Figure 2
Figure 2
SIRPα and its ligands. SIRPα is expressed in cells of myeloid origin and platelets. It has three extracellular Ig domains that function as binding sites for the three known ligands (CD47, SP-A, and SP-B) of SIRPα. Upon ligand binding, SIRPα inhibits immune cell activation through its cytoplasmic ITIM domain (A color version of this figure is available in the online journal.)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Anderson JM, McNally AK. Biocompatibility of implants: lymphocyte/macrophage interactions. Semin Immunopathol 2011; 33: 221–33. - PubMed
    1. Stevens KN, Aldenhoff YB, van der Veen FH, Maessen JG, Koole LH. Bioengineering of improved biomaterials coatings for extracorporeal circulation requires extended observation of blood-biomaterial interaction under flow. J Biomed Biotechnol 2007; 2007: 29464–29464. - PMC - PubMed
    1. Edmunds LH., Jr Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1998; 66(5 Suppl): S12–16. - PubMed
    1. Hill GE. The inflammatory response to cardiopulmonary bypass. Int Anesthesiol Clin 1996; 34: 95–108. - PubMed
    1. Hogue CW, Jr, Palin CA, Arrowsmith JE. Cardiopulmonary bypass management and neurologic outcomes: an evidence-based appraisal of current practices. Anesth Analg 2006; 103: 21–37. - PubMed

Publication types

MeSH terms